Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Background & Aims There are limited prospective data on patients with type 2 diabetes
mellitus (T2DM) specifically enrolled and systematically assessed for advanced fibrosis or …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of chronic liver
disease in the Western world, probably due to the growing prevalence of obesity, metabolic …

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD),
paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …

Dysregulation of the gut microbiome has been implicated in the progression of non-alcoholic
fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis. To determine the diagnostic …

In the past decade, an exciting realization has been that diverse liver diseases—ranging
from nonalcoholic steatohepatitis, alcoholic steatohepatitis and cirrhosis to hepatocellular …